. 2017 Apr 16;9(6):387–404. doi: 10.1177/1758834017702820

Table 2.

Clinical efficacy of osimertinib in advanced NSCLC.

Trial	Phase (n)	ORR	DCR	Median PFS	Remaining alive and progression-free
AURA⁶⁷	I (253)	Overall: 51% T790M-: 21% T790M+: 71%	Overall: 84% T790M-: 61% T790M+: 93%	Overall: 8.2 months T790M-: 2.8 months T790M+: 9.7 months	12 months: 41% 18 months: 29% 24 months: 17%
Pooled AURA extension – AURA-2⁶⁹	II (441)	T790M+: 66%	T790M: 91%	T790M+: 11 months	12 months: 48% 18 months: NA 24 months: NA
AURA 3⁷⁰	III (279)	T790M+: 71%	T790M+: 93%	T790M+: 11 months	6 months: 69% 12 months: 44%

DCR, disease control rate; NSCLC, non-small cell lung cancer; ORR, objective response rate; PFS, progression-free survival; NA, not assessed.